- Business Wire
AstraZeneca today announced that the European Commission (EC) has approved a new indication for Faslodex (fulvestrant) in combination with a CDK4/6 inhibitor, palbociclib, for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer in women who have received prior endocrine therapy.1
David Fredrickson, Executive Vice President, Head of the Oncology Business Unit at AstraZeneca, said: âFor many years fulvestranthas been used as an effective monotherapy treatment for women with hormone receptor positive breast cancer. The first EU approval of fulvestrantfor use in combination with a CDK4/6 inhibitor reinforces the value of fulvestrantas an endocrine agent of choice for advanced breast cancer patients, building on the EU first-line monotherapy approval earlier this year with FALCON.â
The EU approval is based on data from the Phase III PALOMA-3 trial, which showed a statistically significant increase in investigator-assessed median PFS of 4.9 months (9.5 months vs 4.6 months) in patients who received fulvestrant500 mg and palbociclib 125 mg over fulvestrantand placebo (HR: 0Â·46; 95% CI: 0Â·36â0Â·59; p< 0Â·0001).2
â ENDS â
NOTES TO EDITORS
About Advanced Breast Cancer
Advanced/metastatic breast cancer refers to Stage III and IV breast cancer. Stage III disease may also be referred to as locally-advanced breast cancer, while metastatic disease is the most-advanced stage of breast cancer (Stage IV), and occurs when cancer cells have spread beyond the initial tumour site to other organs of the body outside the breast. Since there is no cure for the disease, the goal of current treatment is to delay disease worsening or death. In 2012, there were an estimated 1.67 million new cases worldwide â one in four of all cancer cases. In Europe the estimated 5-year prevalence of breast cancer in 2012 was 1,814,572 cases.
PALOMA-3 is a Phase III international, randomised, double-blind, parallel group, multicentre study, sponsored by Pfizer Inc., of fulvestrantplus palbociclib vs fulvestrantplus placebo conducted in women with HR+/HER2- advanced or metastatic breast cancer, regardless of their menopausal status, whose disease progressed after endocrine therapy. The study evaluated 521 pre/postmenopausal women who were randomised 2:1 to fulvestrantplus
palbociclib or fulvestrantplus placebo. Women who were either premenopausal (meaning they had not reached menopause), or perimenopausal (meaning that their bodies were making the natural transition toward menopause), were therapeutically induced to become postmenopausal and represented 20.7% of the study population.
Patients enrolled in this study had a median age of 57 years (range 29 to 88). The majority of patients in the study were white (74%). All patients had an ECOG (Eastern Cooperative Oncology Group) PS of 0 or 1, and 80% were postmenopausal. All patients had received prior systemic therapy and 75% of patients had received a previous chemotherapy regimen. Twenty-five percent of patients had received no prior therapy in the metastatic disease setting, 60% had visceral metastases, and 22% had bone only disease.
Fulvestrant500 mg was given as two 5 ml injections, one in each buttock, on days 1, 15, 29 and once monthly (28 Â± 3 days) thereafter. Palbociclib was given orally at a dose of 125 mg daily for 21 consecutive days followed by 7 days off treatment. Patients continued to receive their assigned treatment until objective disease progression, symptomatic deterioration, unacceptable toxicity, death, or withdrawal of consent, whichever occurred first.
Fulvestrant is indicated for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy, or with disease relapse on or after adjuvant anti-oestrogen therapy, or disease progression on anti-oestrogen therapy.
In the US, fulvestrantis licensed for use with palbociclib for the treatment of women with HR+, HER2- locally advanced or metastatic breast cancer, whose cancer has progressed after endocrine therapy. In Japan, fulvestrantis also approved for use in combination with any CDK4/6 inhibitor. Fulvestrantrepresents a hormonal treatment approach that helps to slow tumour growth by blocking and degrading the oestrogen receptor â a key driver of disease progression.
Fulvestrantis approved in over 80 countries as a monotherapy to treat ER+ advanced breast cancer patients. It is currently being evaluated in combination with medicines from various drug classes for the treatment of women with HR+ advanced breast cancer.
About AstraZeneca in Oncology
AstraZeneca has a deep-rooted heritage in Oncology and offers a quickly-growing portfolio of new medicines that has the potential to transform patientsâ lives and the Companyâs future. With at least six new medicines to be launched between 2014 and 2020, and a broad pipeline of small molecules and biologics in development, we are committed to advance New Oncology as one of AstraZenecaâs five Growth Platforms focused on lung, ovarian, breast and blood cancers. In addition to our core capabilities, we actively pursue innovative partnerships and investments that accelerate the delivery of our strategy as illustrated by our investment in Acerta Pharma in haematology.
By harnessing the power of four scientific platforms â Immuno-Oncology, Tumour Drivers and Resistance, DNA Damage Response and Antibody-Drug Conjugates â and by championing the development of personalised combinations, AstraZeneca has the vision to redefine cancer treatment and one day eliminate cancer as a cause of death.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of Autoimmunity, Neuroscience and Infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.
1 European Commission. Pharmaceuticals - Community Register. Available from: http://ec.europa.eu/health/documents/community-register/html/h269.htm [Last Accessed November 2017]
2 Cristofanilli M, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, Phase 3 randomised controlled trial. Lancet Oncol. 2016 Apr;17(4):425-39
El productor estadounidense Harvey Weinstein contrató a un equipo para investigar a 91 personas de la industria del cine en un intento por …
El entrenador del París Saint-Germain (PSG), el español Unai Emery, dijo hoy que entiende la necesidad del brasileño Neymar de salir con …
Atlético de Madrid y Roma se enfrentan este miércoles en el estadio Wanda Metropolitano en el encuentro más importante de la quinta …
Las marcas automovilísticas alemanas batirán récord de producción nacional este año, alcanzando en torno a 5,7 millones de unidades, e …
Juventus y FC Barcelona se enfrentan este miércoles en el Juventus Stadium en el encuentro más importante de la quinta jornada de la fase …
La renovación de Leo Messi por el Barcelona, después de que el club la anunciase en el mes de julio, se está enquistando. Los rumores …
El fabricante automovilístico japonés Subaru planea abandonar su producción de vehículos diésel hacia 2020 para centrarse en los …
El proyecto chino del Milan que puso fin a la era Berlusconi la pasada primavera podría tratarse de una macro estafa china que podría …
El director general de Tráfico (DGT), Gregorio Serrano, ha anunciado que se decretarán servicios mínimos del 50% en caso de que los …
Los vídeos que grabaron los acusados de la supuesta violación grupal de los sanfermines han sido exhibidos este martes en la séptima …
Noticias más leidas
Noticias más leidas
Noticias más leidas
Noticias más leidas
Noticias más leidas
La maldición de la Torre Agbar